By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > Haleon Stock: A Hidden Gem In The Consumer Health Market (NYSE:HLN)
News

Haleon Stock: A Hidden Gem In The Consumer Health Market (NYSE:HLN)

News Room
Last updated: 2023/06/11 at 11:18 PM
By News Room
Share
7 Min Read
SHARE

Contents
Investment ThesisStrong Portfolio Of BrandsHuge Market OpportunitiesSolid FinancialsDiscounted ValuationInvestors Takeaway

Investment Thesis

Haleon (NYSE:HLN) was spun off from GSK (GSK) in July last year and its stock price has performed very well after the initial dip in August amid the Zantac litigation. While the company is still relatively new and has little following, it is actually a leader in multiple consumer health markets.

The company has a strong moat thanks to its portfolio of leading brands and should continue to benefit from ongoing market expansions. The latest earnings were also strong with double-digit growth in both the top and the bottom line. Despite the solid fundamentals and growth, its valuation remains meaningfully discounted compared to peers. I believe the current price is compelling therefore I rate the company as a buy.

Chart
Data by YCharts

Strong Portfolio Of Brands

Haleon is a Brentford-based global consumer healthcare company recently spun off from GSK, with a primary focus on oral health, VMS (vitamins, minerals, and supplements), pain relief, respiratory health, and digestive health & others. The company has a strong portfolio of leading brands including Advil, Panadol, Sensodyne, and Voltaren. Thanks to these popular brands, it currently has a leading market share in 4 out of its 5 segments.

The strong branding and penetration give the company a formidable moat as customers are often reluctant to switch brands after they get comfortable with one, especially for health-related products. The stickiness of these products subsequently translates to much better pricing power as well, which helps the company steadily grow at above-market rates.

Haleon

Haleon

Huge Market Opportunities

Considering the company’s leading portfolio and market position, it should be well-positioned to benefit from its large and expanding TAM (total addressable market). According to the company, the 5 segments combined present a TAM of £150 billion that is estimated to grow at a CAGR (compounded annual growth rate) of 3.5% in the medium term. Allied Market Research is even more optimistic and expects the market to reach $574.4 billion by 2032.

The market expansion should be very durable due to the aging population and increasing health awareness. For instance, the percentage of the world’s population over 60 years old is expected to grow from 12% in 2015 to 22% in 2050, according to the World Health Organization. Health awareness is also on the rise due to the outbreak of the pandemic in 2020. These catalysts should continue to help drive the demand for consumer health products.

Haleon

Haleon

Solid Financials

Haleon announced its first-quarter earnings last month and the results are very solid considering the current macro backdrop. The company reported revenue of £2.99 billion, up 13.7% YoY (year over year) compared to £2.63 billion.

Organic revenue growth was 9.9%. The growth was driven by a 2.8% increase in volume and a 7.1% increase in pricing. The respiratory health segment was extremely strong amid the increase in cold and flu cases, with revenue up 39% from £367 million to £510 million. The pain relief segment also saw upbeat traction, with revenue up 14% from £635 million to £724 million.

The bottom line was also strong thanks to favorable price mix and lowered spending. Gross profit increased 14.3% YoY from £1.61 billion to £1.84 billion. The gross profit margin expanded 20 basis points from 61.4% to 61.6%. SG&A (selling, general, and administration) expenses as a percentage of revenue declined 330 basis points from 41.3% to 38%, as the company benefited from better operating leverage.

This resulted in the operating income up 34.5% YoY from £466 million to £627 million. The operating margin also increased 330 basis points from 17.7% to 21%. The diluted EPS was £4.2 compared to £3.7, up 13.5% YoY.

Discounted Valuation

Despite the rise in share price in the past few months, Haleon still looks attractively priced. The company is currently trading at a fwd PE ratio of 17.9x, which is more than justified in my opinion.

For instance, the multiple is lower than other notable consumer healthcare companies such as Kenvue (KVUE), Colgate-Palmolive (CL), and Procter & Gamble (PG). The peer group has an average fwd PE ratio of 23.1x, which represents a meaningful premium of 29.1%. Haleon’s latest revenue growth of 13.7% also vastly outpaced peers, which reported growth of roughly mid to high single digits. The sizeable valuation gap seems unjustified and I believe the company’s valuation should eventually catch up to peers.

Investors Takeaway

I believe Haleon has the potential to become a great compounder. Its strong portfolio of leading brands alongside the organic market expansion should drive durable and consistent growth in the long run. The company should also demonstrate great resiliency as most of its products are non-discretionary. This is important in the near term as the economy continues to slow down amid the rise in interest rates. While the company has strong fundamentals and growth, its current valuation remains meaningfully below peers.

There is risk regarding the litigation with Zantac but I am not concerned as GSK is the only defendant in the July trial and the company stated that they have never marketed the product. There should be ample upside potential if the company can catch up on valuation therefore I rate it as a buy.

Read the full article here

News Room June 11, 2023 June 11, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Trump to speak to Putin and Zelenskyy in fresh peace bid

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

Israel expands Gaza ground offensive after days of air strikes

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

The deal that has spurred Apollo’s plan to remake Wall Street

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Does Moody’s US downgrade matter?

Stay informed with free updatesSimply sign up to the Capital markets myFT…

Crypto traders who won dinner with Donald Trump also made big profits

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

- Advertisement -
Ad imageAd image

You Might Also Like

News

Trump to speak to Putin and Zelenskyy in fresh peace bid

By News Room
News

Israel expands Gaza ground offensive after days of air strikes

By News Room
News

The deal that has spurred Apollo’s plan to remake Wall Street

By News Room
News

Does Moody’s US downgrade matter?

By News Room
News

Crypto traders who won dinner with Donald Trump also made big profits

By News Room
News

The ‘Taco’ factor has spurred markets higher

By News Room
News

BT nears deal to sell TNT Sports stake to Warner Bros Discovery

By News Room
News

UK overtakes China as second-largest US Treasury holder

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?